Search

Your search keyword '"Hebert, K."' showing total 289 results
Start Over Author "Hebert, K."
289 results on '"Hebert, K."'

1. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types

Author

Matossian, M. D., Chang, T., Wright, M. K., Burks, H. E., Elliott, S., Sabol, R. A., Wathieu, H., Windsor, G. O., Alzoubi, M. S., King, C. T., Bursavich, J. B., Ham, A. M., Savoie, J. J., Nguyen, K., Baddoo, M., Flemington, E., Sirenko, O., Cromwell, E. F., Hebert, K. L., Lau, F., Izadpanah, R., Brown, H., Sinha, S., Zabaleta, J., Riker, A. I., Moroz, K., Miele, L., Zea, A. H., Ochoa, A., Bunnell, B. A., Collins-Burow, B. M., Martin, E. C., and Burow, M. E.

Published
2022
Full Text
View/download PDF

18. In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types

Author

Matossian, M. D., primary, Chang, T., additional, Wright, M. K., additional, Burks, H. E., additional, Elliott, S., additional, Sabol, R. A., additional, Wathieu, H., additional, Windsor, G. O., additional, Alzoubi, M. S., additional, King, C. T., additional, Bursavich, J. B., additional, Ham, A. M., additional, Savoie, J. J., additional, Nguyen, K., additional, Baddoo, M., additional, Flemington, E., additional, Sirenko, O., additional, Cromwell, E. F., additional, Hebert, K. L., additional, Lau, F., additional, Izadpanah, R., additional, Brown, H., additional, Sinha, S., additional, Zabaleta, J., additional, Riker, A. I., additional, Moroz, K., additional, Miele, L., additional, Zea, A. H., additional, Ochoa, A., additional, Bunnell, B. A., additional, Collins-Burow, B. M., additional, Martin, E. C., additional, and Burow, M. E., additional

Published
2021
Full Text
View/download PDF

22. Status and Management of World Sea Urchin Fisheries

Author

Hur, S, primary, Hunter, M, additional, Hebert, K, additional, Botsford, L, additional, Johnson, C, additional, Einarsson, S, additional, Campbell, A, additional, Ballesteros, E, additional, Andrew, N, additional, Gerring, P, additional, Dixon, J, additional, Bazhin, A, additional, Juinio-Meñez, M, additional, Barnes, D, additional, Creaser, E, additional, Bradbury, A, additional, Agatsuma, Y, additional, Kalvass, P, additional, Miller, R, additional, Moreno, C, additional, Palleiro, J, additional, Rivas, D, additional, Robinson, S, additional, Schroeter, S, additional, Steneck, R, additional, Vadas, R, additional, Woodby, D, additional, and Xiaoqi, Z, additional

Published
2002
Full Text
View/download PDF

23. Foner, Eric. The second founding: how the Civil War and Reconstruction remade the Constitution

Author

Hebert, K.

Subjects
The Second Founding: How the Civil War and Reconstruction Remade the Constitution (Nonfiction work) -- Foner, Eric, Books -- Book reviews, Library and information science, Literature/writing
Abstract

Foner, Eric. The second founding: how the Civil War and Reconstruction remade the Constitution. W.W. Norton, 2019. 224p index ISBN 9780393652574 cloth, $26.95; ISBN 9780393652581 ebook, contact publisher for price [...]

Published
2020

38. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia

Author

Rice, C., Eikema, D.J., Marsh, J.C., Knol, C., Hebert, K., Putter, H., Peterson, E., Deeg, H.J., Halkes, S., Pidala, J., Anderlini, P., Tischer, J., Kroger, N., McDonald, A., Antin, J.H., et al., Schaap, N.P.M., Hallek, M., Einsele, H., Mathews, V., Kapoor, N., Boelens, J.J., Mufti, G.J., Potter, V., Tour, R. Pefault de la, Eapen, M., Dufour, C., Rice, C., Eikema, D.J., Marsh, J.C., Knol, C., Hebert, K., Putter, H., Peterson, E., Deeg, H.J., Halkes, S., Pidala, J., Anderlini, P., Tischer, J., Kroger, N., McDonald, A., Antin, J.H., et al., Schaap, N.P.M., Hallek, M., Einsele, H., Mathews, V., Kapoor, N., Boelens, J.J., Mufti, G.J., Potter, V., Tour, R. Pefault de la, Eapen, M., and Dufour, C.

Abstract

Contains fulltext : 202835.pdf (publisher's version ) (Open Access), We report on 499 patients with severe aplastic anemia aged >/= 50years who underwent hematopoietic cell transplantation (HCT) from HLA-matched sibling (n=275, 55%) or HLA-matched (8/8) unrelated donors (n=187, 37%) between 2005 and 2016. The median age at HCT was 57.8 years; 16% of patients were 65 to 77years old. Multivariable analysis confirmed higher mortality risks for patients with performance score less than 90% (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.03 to 1.92; P=.03) and after unrelated donor transplantation (HR, 1.47; 95% CI, 1 to 2.16; P=.05). The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-matched sibling transplant were 66% (range, 57% to 75%) and 57% (range, 47% to 76%), respectively. The corresponding probabilities after HLA-matched unrelated donor transplantation were 57% (range, 48% to 67%) and 48% (range, 36% to 59%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease (GVHD) risks were higher for patients aged 65years or older (subdistribution HR [sHR], 1.7; 95% confidence interval, 1.07 to 2.72; P=.026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor (CNI)+methotrexate (sHR, .52; 95% CI, .33 to .81; P=.004) and CNI alone or with other agents (sHR, .27; 95% CI, .14 to .53; P < .001) compared with CNI+mycophenolate. Although donor availability is modifiable only to a limited extent, choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes.

Published
2019

44. Four-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions: The SPIRIT II Trial

Author

Garg, Scot, Serruys, PWJC (Patrick), Miquel-Hebert, K, and Cardiology

Subjects
cardiovascular diseases
Abstract

This report describes the 4-year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus-eluting stent (EES), or the TAXUS paclitaxel-eluting stent. At 4-year clinical follow-up, which was available in 256 (85.3%) patients, treatment with EES lead to a trend for lower rates of ischemia-driven major adverse cardiovascular events, a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (EES 7.7% vs. paclitaxel-eluting stent 16.4%, P = 0.056). Treatment with EES also resulted in a trend toward lower rates of cardiac death and numerically lower rates of myocardial infarction, ischemia-driven target lesion revascularization, and stent thrombosis. Overall, this study reports numerically fewer clinical events in patients treated with EES at 4-year follow-up, which is consistent with results from earlier follow-up. (C) 2010 Wiley-Liss, Inc.

Published
2011

46. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study

Author

Bruining, Nico, de Winter, S, Roelandt, Jos, Regar, Evelyn, Heller, I, van Domburg, Ron, Hamers, R (Ronald), Onuma, Yoshinobu, Dudek, D, Webster, MWI, Thuesen, L, Ormiston, JA, Cheong, WF, Miguel-Hebert, K, Veldhof, S, Serruys, PWJC (Patrick), Cardiology, and Cardiothoracic Surgery

Subjects
SDG 3 - Good Health and Well-being
Abstract

Objectives The aim of this study was to investigate the feasibility of using quantitative differential echogenicity to monitor the in vivo absorption process of a drug-eluting poly-l-lactic-acid (PLLA) bioabsorbable stent (BVS, Abbott Vascular, Santa Clara, California). Background A new bioabsorbable, balloon-expanded coronary stent was recently evaluated in a first-in-man study. Little is known about the absorption process in vivo in diseased human coronary arteries. Methods In the ABSORB (Clinical Evaluation of the BVS everolimus eluting stent system) study, 30 patients underwent treatment with the BVS coronary stent system and were examined with intracoronary ultrasound (ICUS) after implantation, at 6 months and at 2-year follow-up. Quantitative ICUS was used to measure dimensional changes, and automated ICUS-based tissue composition software (differential echogenicity) was used to quantify plaque compositional changes over time in the treated regions. Results The BVS struts appeared as bright hyperechogenic structures and showed a continuous decrease of their echogenicity over time, most likely due to the polymer degradation process. In 12 patients in whom pre-implantation ICUS was available, at 2 years the percentage-hyperechogenic tissue was close to pre-implantation values, indicating that the absorption process was either completed or the remaining material was no longer differentially echogenic from surrounding tissues. Conclusions Quantitative differential echogenicity is a useful plaque compositional measurement tool. Furthermore, it seems to be valuable for monitoring the absorption process of bioabsorbable coronary stents made of semi-crystalline polymers. (J Am Coll Cardiol Intv 2010;3:449-56) (C) 2010 by the American College of Cardiology Foundation

Published
2010
Full Text
View/download PDF

47. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.

Author

Li X., Miquel-Hebert K., Serruys P.W., Ormiston J.A., Diletti R., Farooq V., Girasis C., Bourantas C., Onuma Y., Heo J.H., Gogas B.D., Van Geuns R.-J., Regar E., De Bruyne B., Dudek D., Thuesen L., Chevalier B., McClean D., Windecker S., Whitbourn R.J., Smits P., Garcia-Garcia H.M., Koolen J., Veldhof S., Meredith I., Li X., Miquel-Hebert K., Serruys P.W., Ormiston J.A., Diletti R., Farooq V., Girasis C., Bourantas C., Onuma Y., Heo J.H., Gogas B.D., Van Geuns R.-J., Regar E., De Bruyne B., Dudek D., Thuesen L., Chevalier B., McClean D., Windecker S., Whitbourn R.J., Smits P., Garcia-Garcia H.M., Koolen J., Veldhof S., and Meredith I.

Abstract

Background: The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. Method(s): In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The prereference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and >=2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. Result(s): At 2-year angiographic follow-up no differences in late lumen loss (0.29+/-0.16 mm vs 0.25+/-0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25+/-3.47 mm2 vs 13.09+/-3.38 mm2 p=0.0015), scaffold area (5.76+/-0.96 mm2 vs 6.41+/-1.30 mm2 p=0.0008) and lumen area (5.71+/-0.98 mm2 vs 6.20+/-1.27 mm 2 p=0.0155) between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events (7.3% vs 10.2%, p=0.7335), myocardial infarction (4.9% vs 1.7%, p=0.5662) or ischaemia-driven target lesion revascularisation (2.4% vs 8.5%, p=0.3962) were reported between small and large vessels. No deaths or scaffold thrombosis were observed. Conclusion(s): Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels.

Published
2013

48. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold

Author

Brugaletta, S, Garcia Garcia, Hector, Garg, Scot, Gomez Lara, Josep, Diletti, Roberto, Onuma, Yoshinobu, van Geuns, Robert Jan, McClean, D, Dudek, D, Thuesen, L, Chevalier, B, Windecker, S, Whitbourn, R, Dorange, C, Miquel-Hebert, K, Sudhir, K, Ormiston, JA, Serruys, PWJC (Patrick), Brugaletta, S, Garcia Garcia, Hector, Garg, Scot, Gomez Lara, Josep, Diletti, Roberto, Onuma, Yoshinobu, van Geuns, Robert Jan, McClean, D, Dudek, D, Thuesen, L, Chevalier, B, Windecker, S, Whitbourn, R, Dorange, C, Miquel-Hebert, K, Sudhir, K, Ormiston, JA, and Serruys, PWJC (Patrick)

Abstract

Implantation of a coronary stent results in a mechanical enlargement of the coronary lumen with stretching of the surrounding atherosclerotic plaque. Using intravascular ultrasound virtual-histology (IVUS-VH) we examined the temporal changes in composition of the plaque behind the struts (PBS) following the implantation of the everolimus eluting bioresorbable vascular scaffold (BVS). Using IVUS-VH and dedicated software, the composition of plaque was analyzed in all patients from the ABSORB B trial who were imaged with a commercially available IVUS-VH console (s5i system, Volcano Corporation, Rancho Cordova, CA, USA) post-treatment and at 6-month follow-up. This dedicated software enabled analysis of the PBS after subtraction of the VH signal generated by the struts. The presence of necrotic core (NC) in contact with the lumen was also evaluated at baseline and follow-up. IVUS-VH data, recorded with s5i system, were available at baseline and 6-month follow-up in 15 patients and demonstrated an increase in both the area of PBS (2.45 +/- A 1.93 mm(2) vs. 3.19 +/- A 2.48 mm(2), P = 0.005) and the external elastic membrane area (13.76 +/- A 4.07 mm(2) vs. 14.76 +/- A 4.56 mm(2), P = 0.006). Compared to baseline there was a significant progression in the NC (0.85 +/- A 0.70 mm(2) vs. 1.21 +/- A 0.92 mm(2), P = 0.010) and fibrous tissue area (0.88 +/- A 0.79 mm(2) vs. 1.15 +/- A 1.05 mm(2), P = 0.027) of the PBS. The NC in contact with the lumen in the treated segment did not increase with follow-up (7.33 vs. 6.36%, P = 0.2). Serial IVUS-VH analysis of BVS-treated lesions at 6-month demonstrated a progression in the NC and fibrous tissue content of PBS.

Published
2011

49. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial

Author

Diletti, R., primary, Farooq, V., additional, Girasis, C., additional, Bourantas, C., additional, Onuma, Y., additional, Heo, J. H., additional, Gogas, B. D., additional, van Geuns, R.-J., additional, Regar, E., additional, de Bruyne, B., additional, Dudek, D., additional, Thuesen, L., additional, Chevalier, B., additional, McClean, D., additional, Windecker, S., additional, Whitbourn, R. J., additional, Smits, P., additional, Koolen, J., additional, Meredith, I., additional, Li, X., additional, Miquel-Hebert, K., additional, Veldhof, S., additional, Garcia-Garcia, H. M., additional, Ormiston, J. A., additional, and Serruys, P. W., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results